Site Editor

Sandy Srinivas, MD


Long-Term Outcomes Support Image-Guided Therapy for Localized Prostate Cancer

By: Lauren Velentzas
Posted: Tuesday, March 26, 2024

Steven Raman, MD, FSAR, FSIR, of the David Geffen School of Medicine at the University of California, and colleagues reported on the 5-year outcomes of MRI-guided transurethral ultrasound ablation (TULSA) during the 2024 Society of Interventional Radiology (SIR) Annual Meeting (Abstract 135). The treatment demonstrated durable oncologic control, safety, and functional preservation after a single one-gland procedure.

“This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency. The success of TULSA represents a revolution in whole-gland treatment for prostate cancer,” said Dr. Raman in an SIR press release.

The study consisted of 115 men with Gleason grade 2 and 1 prostate cancer who received a single whole-gland TULSA treatment. They represented 13 sites in 5 countries. Of them, 21.7% received salvage treatment with surgery or radiation. After 1 year, cancer was undetectable on follow-up biopsy in 76%, and after 5 years, patients saw prostate volume reduced by 92% and PSA levels reduced from 6.3 ng/mL to 0.63 ng/mL. Grade 3 adverse events were reported in 10% of patients, with no grade 4 events observed. A total of 92% of patients also recovered continence, and 87% experienced preserved erectile function.

A randomized controlled study known as the CAPTAIN trial, which will compare TULSA with radical prostatectomy ( identifier NCT05027477), is currently recruiting.

Disclosure: No disclosure information for the study authors was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.